Dronabinol
Mechanism :
Dronabinol is a cannabinoid which has complex effects on the central nervous system (CNS), including central sympathomimetic activity. Cannabinoid receptors have been discovered in neural tissues. These receptors may play a role in mediating the effects of dronabinol and other cannabinoids.
Indication :
- Nausea and vomiting associated with cancer chemotherapy
Contraindications :
Dronabinol should not be given to patients sensitive to marijuana, other cannabinoids or sesame oil. Dronabinol should not be given to patients with a history of psychotic disorders or those judged to be intolerant of the drug.
Dosing :
Initial Dose:
5 mg/m² dose given 1 to 3 hours prior to administration of chemotherapy.
Repeat Dose:
5 mg/m² dose every 2 to 4 hours following chemotherapy, when necessary, and may be increased gradually upto 15 mg/m² for a total of not more than 4 to 6 doses/day usually for 1 or 2 days.
Adverse Effect :
Dizziness, drowsiness, transient impairment of sensory and perceptual functions, muscular pains, asthenia, syncope, psychotropic effects, tinnitus, nightmares, facial flushing, speech difficulty, perspiration, diarrhea, faecal incontinence.
Interaction :
Avoid doxylamine, sodium oxybate.
Hepatic Dose :
Use with caution as it is metabolized in the liver and there is increased risk for adverse reactions.